Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Shares Issued (2021 - 2024)

Lyra Therapeutics (LYRA) has disclosed Shares Issued for 4 consecutive years, with $3000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Shares Issued fell 25.0% to $3000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $3000.0, a 97.09% decrease, with the full-year FY2024 number at $3000.0, down 97.09% from a year prior.
  • Shares Issued was $3000.0 for Q1 2024 at Lyra Therapeutics, up from $2000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $331000.0 in Q2 2021 to a low of $2000.0 in Q3 2023.
  • A 4-year average of $89750.0 and a median of $9500.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: plummeted 96.95% in 2022, then fell 25.0% in 2024.
  • Lyra Therapeutics' Shares Issued stood at $11000.0 in 2021, then decreased by 27.27% to $8000.0 in 2022, then plummeted by 75.0% to $2000.0 in 2023, then skyrocketed by 50.0% to $3000.0 in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Shares Issued are $3000.0 (Q1 2024), $2000.0 (Q3 2023), and $97000.0 (Q2 2023).